Trial Profile
A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction (VICTORIA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms VICTORIA
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 01 Sep 2023 Results assessing herence to guideline use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, angiotensin receptor-neprilysin inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. published in the Circulation: Heart Failure
- 01 Sep 2023 Results published in the European Journal of Heart Failure
- 28 Aug 2023 Results of post hoc analysis from VICTORIA trial assessing impact of type 2 diabetes mellitus on outcomes in patients with worsening heart failure with reduced ejection fraction and to assess the efficacy of vericiguat in these patients presented at the ESC Congress 2023 Annual Congress of the European Society of Cardiology.